AbbVie Inc. closed 15.13% below its 52-week high of $218.66, which the company reached on March 10th.

After a two-year surge of 53%, the stock market has been taken for a wild ride in 2025, driven by uncertainties surrounding ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 93% based on the firm’s underlying fundamentals and the stock’s valuation.

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AbbVie is strutting into 2025 like it owns the lab, thanks to a performance cocktail of smart acquisitions, clinical wins, ...

AbbVie’s stock faced a chilly reception on May 6, plunging 4.55% and ending the day at $187.15. Despite strong fundamentals ...

Richard A. Gonzalez is the founder of AbbVie Ltd. (United Kingdom) since 2013, holding the title of Chairman & Chief Executive Officer. Current jobs include Chief Executive Officer at AbbVie ...